Zibo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zibo Chen has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- David Baker
University of Washington, Howard Hughes Medical Institute
10 shared publications - Scott E. Boyken
Outpace Bio, Seattle, WA, USA
9 shared publications - Ethan Dmitrovsky
Frederick National Laboratory for Cancer Research 1 Molecular Pharmacology Program, Cancer Research Technology Program Frederick, Maryland
7 shared publications - Jason Roszik
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
7 shared publications - Masanori Kawakami
Department of Respiratory Medicine, Graduate School of Medicine The University of Tokyo Tokyo Japan
7 shared publications Mengxuan Jia
Department of Chemistry and Biochemistry, The Ohio State University, Columbus, USA
7 shared publications
Latest Publications
- 13 July 2026
- Published by Elsevier in Cell Systems
- Vol. 17 (9) , 101658
Multimolecular proofreading overcomes the activity-fidelity trade-off
- 13 July 2026
- Published by Elsevier in Cell Systems
- Vol. 17 (9) , 101658
Multimolecular proofreading overcomes the activity-fidelity trade-off
- 26 May 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (7) , 1084-1088
A framework for building a synthetic cell from the SynCell Asia Initiative
- 26 May 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (7) , 1084-1088
A framework for building a synthetic cell from the SynCell Asia Initiative
- Open Access
Multimolecular proofreading overcomes the activity-fidelity trade-off
SUMMARY: Accurate signal processing is essential for proper cell functions, and can be achieved through kinetic proofreading, where an enzyme undergoes sequential state transitions and irreversible deactivation to enable high fidelity. However, synthetically constructing a biological proofreading system has been hindered by the difficulty in engineering single molecular state transitions. Here, we designed a protein circuit that combines diffusion and endocytosis to enable kinetic proofreading at the multimolecular level, without the conservation of total enzymes implicitly assumed in classic kinetic proofreading. Simulations revealed a previously overlooked yet experimentally crucial trade-off between circuit activity and fidelity, and theoretical analysis confirmed it to be fundamental in all kinetic proofreading systems. By integrating self-activation and mutual inhibition mechanisms, the circuit overcomes this activity-fidelity trade-off within biologically plausible parameter regimes. Our results extend proofreading schemes from single enzymes to a multimolecular context, and represent a practical and generalizable strategy for constructing high-fidelity synthetic biological circuits. HIGHLIGHTS: We design a multimolecular and multicellular proofreading circuit A previously overlooked yet practically relevant trade-off arises between circuit activity and fidelity The activity-fidelity trade-off is fundamental in all kinetic proofreading circuits Self-activation and mutual inhibition mechanisms collectively overcome the activity-fidelity trade-off
Open AccessMultimolecular proofreading overcomes the activity-fidelity trade-off
SUMMARY: Accurate signal processing is essential for proper cell functions, and can be achieved through kinetic proofreading, where an enzyme undergoes sequential state transitions and irreversible deactivation to enable high fidelity. However, synthetically constructing a biological proofreading system has been hindered by the difficulty in engineering single molecular state transitions. Here, we designed a protein circuit that combines diffusion and endocytosis to enable kinetic proofreading at the multimolecular level, without the conservation of total enzymes implicitly assumed in classic kinetic proofreading. Simulations revealed a previously overlooked yet experimentally crucial trade-off between circuit activity and fidelity, and theoretical analysis confirmed it to be fundamental in all kinetic proofreading systems. By integrating self-activation and mutual inhibition mechanisms, the circuit overcomes this activity-fidelity trade-off within biologically plausible parameter regimes. Our results extend proofreading schemes from single enzymes to a multimolecular context, and represent a practical and generalizable strategy for constructing high-fidelity synthetic biological circuits. HIGHLIGHTS: We design a multimolecular and multicellular proofreading circuit A previously overlooked yet practically relevant trade-off arises between circuit activity and fidelity The activity-fidelity trade-off is fundamental in all kinetic proofreading circuits Self-activation and mutual inhibition mechanisms collectively overcome the activity-fidelity trade-off
- Open Access
- 31 December 2025
- Published by Shenzhen Medical Academy of Research and Translation
De novo design of dual-topology membrane transporters
The transport of molecules across biological membranes is essential for life, allowing cells to acquire nutrients, remove waste, maintain cellular homeostasis and communicate with their environment. Although there have been advances in de novo design of functional transmembrane proteins, designing synthetic transporters that robustly and selectively transport specific small molecules across membranes has remained a significant challenge. In this study, we present the de novo design of dual-topology membrane transporters that achieve substrate-specific transport through a rationally programmed conformational cycle. By integrating symmetric backbone assembly with deep learning–guided sequence optimization, we designed 3-TM proteins that insert in opposite orientations and assemble into antiparallel dimers, forming a putative central substrate binding site that enables alternating access to either side of the membrane. These designed transporters mediate selective uptake of small-molecule dyes in both living cells and artificial liposomes, driven by substrate concentration gradients, resembling those of natural uniporters. Cryo-EM structures reveal high fidelity to the design models, and functional assays corroborate the dual-topology architecture and mechanism of action. Here we show that functional, dynamic membrane transporters can be built from the ground up with atomic-level precision—providing insights into the evolutionary origins of transporters and opening new avenues for applications, including targeted drug delivery and metabolic pathway engineering.
- 31 December 2025
- Published by Shenzhen Medical Academy of Research and Translation
Open AccessDe novo design of dual-topology membrane transporters
The transport of molecules across biological membranes is essential for life, allowing cells to acquire nutrients, remove waste, maintain cellular homeostasis and communicate with their environment. Although there have been advances in de novo design of functional transmembrane proteins, designing synthetic transporters that robustly and selectively transport specific small molecules across membranes has remained a significant challenge. In this study, we present the de novo design of dual-topology membrane transporters that achieve substrate-specific transport through a rationally programmed conformational cycle. By integrating symmetric backbone assembly with deep learning–guided sequence optimization, we designed 3-TM proteins that insert in opposite orientations and assemble into antiparallel dimers, forming a putative central substrate binding site that enables alternating access to either side of the membrane. These designed transporters mediate selective uptake of small-molecule dyes in both living cells and artificial liposomes, driven by substrate concentration gradients, resembling those of natural uniporters. Cryo-EM structures reveal high fidelity to the design models, and functional assays corroborate the dual-topology architecture and mechanism of action. Here we show that functional, dynamic membrane transporters can be built from the ground up with atomic-level precision—providing insights into the evolutionary origins of transporters and opening new avenues for applications, including targeted drug delivery and metabolic pathway engineering.
- Open Access
- 15 October 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (43) , 39321-39329
Multivalency Enables Signal Processing at Single Protein Level
Synthetic signal processing in cells can be achieved through complex networks of molecules or simpler, single-molecule-based mechanisms. The latter approach stands out for its reduced genetic load and ease of delivery. Multivalent protein binders are such single-molecule signal processors that exhibit distinct behaviors when interacting with cells presenting various antigen profiles. However, a quantitative and precise method to design multivalent interactions in the context of cell surface binding is still lacking. Here, we developed Multivalent Antigen Sensing Simulator (MASS) to guide the design of such multivalent proteins. We verified the model through in vitro and cell binding experiments, showing the predictive accuracy of our model in designing multivalent binders to sense cell surface antigen identities and elicit selective killing. Our model also accurately captured, which was verified via experiments, the nonmonotonic interplay between valency and monovalent affinity in designing multivalent binders that sense cell surface antigen densities. Our work suggests practical guidelines in designing multivalent proteins that could simultaneously sense both antigen identities and densities and enables fast and precise in silico prescreening of multivalent protein binders.
- 15 October 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (43) , 39321-39329
Open AccessMultivalency Enables Signal Processing at Single Protein Level
Synthetic signal processing in cells can be achieved through complex networks of molecules or simpler, single-molecule-based mechanisms. The latter approach stands out for its reduced genetic load and ease of delivery. Multivalent protein binders are such single-molecule signal processors that exhibit distinct behaviors when interacting with cells presenting various antigen profiles. However, a quantitative and precise method to design multivalent interactions in the context of cell surface binding is still lacking. Here, we developed Multivalent Antigen Sensing Simulator (MASS) to guide the design of such multivalent proteins. We verified the model through in vitro and cell binding experiments, showing the predictive accuracy of our model in designing multivalent binders to sense cell surface antigen identities and elicit selective killing. Our model also accurately captured, which was verified via experiments, the nonmonotonic interplay between valency and monovalent affinity in designing multivalent binders that sense cell surface antigen densities. Our work suggests practical guidelines in designing multivalent proteins that could simultaneously sense both antigen identities and densities and enables fast and precise in silico prescreening of multivalent protein binders.
- Open Access
- 13 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6727) , 1243-1250
A synthetic protein-level neural network in mammalian cells
Artificial neural networks provide a powerful paradigm for nonbiological information processing. To understand whether similar principles could enable computation within living cells, we combined de novo–designed protein heterodimers and engineered viral proteases to implement a synthetic protein circuit that performs winner-take-all neural network classification. This “perceptein” circuit combines weighted input summation through reversible binding interactions with self-activation and mutual inhibition through irreversible proteolytic cleavage. These interactions collectively generate a large repertoire of distinct protein species stemming from up to eight coexpressed starting protein species. The complete system achieves multi-output signal classification with tunable decision boundaries in mammalian cells and can be used to conditionally control cell death. These results demonstrate how engineered protein-based networks can enable programmable signal classification in living cells.
- 13 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 386 (6727) , 1243-1250
Open AccessA synthetic protein-level neural network in mammalian cells
Artificial neural networks provide a powerful paradigm for nonbiological information processing. To understand whether similar principles could enable computation within living cells, we combined de novo–designed protein heterodimers and engineered viral proteases to implement a synthetic protein circuit that performs winner-take-all neural network classification. This “perceptein” circuit combines weighted input summation through reversible binding interactions with self-activation and mutual inhibition through irreversible proteolytic cleavage. These interactions collectively generate a large repertoire of distinct protein species stemming from up to eight coexpressed starting protein species. The complete system achieves multi-output signal classification with tunable decision boundaries in mammalian cells and can be used to conditionally control cell death. These results demonstrate how engineered protein-based networks can enable programmable signal classification in living cells.
- Open Access
- 23 August 2024
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 32
What can protein circuit design learn from DNA nanotechnology?
- 23 August 2024
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 32
Open AccessWhat can protein circuit design learn from DNA nanotechnology?
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.